New Alzheimer's drug enters first human tests

NCT ID NCT07301502

Not yet recruiting Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

Summary

This is a first-in-human study to check if a new drug called AK152 is safe and how it behaves in the body. It will involve 108 healthy volunteers and people with early Alzheimer's disease. The main goal is to find the right dose and understand side effects before testing if it helps control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Frist Affiliated Hospital of USTC

    Hefei, Anhui, China

Conditions

Explore the condition pages connected to this study.